Clinical Features of Children With MOG-IgG Who Fulfill Criteria of Multiple Sclerosis and Overlapping Disorders
Fonseca, Elianet Gisell (Hospital Clínic i Provincial de Barcelona)
Olivé-Cirera, Gemma (Institut de Recerca Sant Pau)
Chen, Li Wen (National Cheng Kung University)
Paredes-Carmona, Fernando (Hospital Arnau de Vilanova)
Vázquez-López, Mara (Hospital Gregorio Marañon)
Felipe-Rucián, Ana (Hospital Universitari Vall d'Hebron)
Romeu, Gemma (Universitat de barcelona)
Martinez-Hernandez, Eugenia (University of Pennsylvania)
Blanco Morgado, Yolanda (Hospital Clínic i Provincial de Barcelona)
Sepulveda, Maria (Hospital Clínic i Provincial de Barcelona)
Saiz, Albert (Hospital Clínic i Provincial de Barcelona)
Dalmau, Josep (Hospital Clínic i Provincial de Barcelona)
Armangue, Thais (Hospital Clínic i Provincial de Barcelona)
Nuñez Enamorado, Noem (Hospital 12 de Octubre (Madrid))
Boyero Duran, Sabas (Hospital Universitario de Cruces (Barakaldo, País Basc))
Mendibe-Bilbao, María del Mar (Hospital Universitario de Cruces (Barakaldo, País Basc))
Visa-Reñé, Nuria (Hospital Arnau de Vilanova)
Universitat Autònoma de Barcelona. Departament de Medicina

Data:	2025
Resum:	ObjectivesThe aim of this study was to report the clinical features, disease-modifying treatment (DMT) response, and outcomes of children with MOG-IgG who fulfill the 2017 McDonald criteria for multiple sclerosis (MS). MethodsThis prospective observational study included children (<18 years) with a suspected acquired demyelinating syndrome (ADS) whose serum or CSF was positive for MOG-IgG, who met the indicated MS criteria, and who had ≥1 year of clinical follow-up. MOG-IgG was tested using live cell-based assays. ResultsOf 554 children with confirmed ADS (196 with MOG-IgG), 8 (median age 11 years, interquartile range 9-14) harbored MOG-IgG and fulfilled MS criteria: 2 had typical MS and 6 had overlapping MOGAD-MS features at onset, but 5 of the latter group developed an MS-like course during follow-up. Five of 7 patients with assessable samples were Epstein-Barr virus seropositive at disease onset, and all 8 had persistent silent radiologic activity with lesional location and morphology suggestive of MS, leading to initiation of DMT. All initial treatments were well tolerated, but eventually, 7 of 8 children (88%) required high-efficacy DMT. DiscussionIn this pediatric cohort, 4% of patients with MOG-IgG met criteria for MS. The clinical-radiologic spectrum ranged from typical MS to overlapping MOGAD-MS, and patients usually required high-efficacy DMT.
Ajuts:	Instituto de Salud Carlos III PI21/00316
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Llengua:	Anglès
Document:	Article de revisió ; recerca ; Versió publicada
Matèria:	Adolescent ; Autoantibodies ; Child ; Demyelinating Autoimmune Diseases, CNS ; Female ; Follow-Up Studies ; Humans ; Immunoglobulin G ; Male ; Multiple Sclerosis ; Myelin-Oligodendrocyte Glycoprotein ; Prospective Studies
Publicat a:	Neurology® neuroimmunology & neuroinflammation, Vol. 12, Num. 4 (January 2025) , art. e200400, ISSN 2332-7812

DOI: 10.1212/NXI.0000000000200400
PMID: 40505071

7 p, 456.1 KB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Recerca Sant Pau
Articles > Articles de recerca
Articles > Articles publicats